Literature DB >> 17428843

Plasma gelsolin: in search of its raison d'etre. Focus on "Modifications of cellular responses to lysophosphatidic acid and platelet-activating factor by plasma gelsolin".

Mark J Dinubile.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17428843     DOI： 10.1152/ajpcell.00007.2007

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN： 0363-6143            Impact factor:   4.249


× No keyword cloud information.
  11 in total

1.  Maternal serum proteome changes between the first and third trimester of pregnancy in rural southern Nepal.

Authors:  P F Scholl; R N Cole; I Ruczinski; M Gucek; R Diez; A Rennie; C Nathasingh; K Schulze; P Christian; J D Yager; J D Groopman; K P West
Journal:  Placenta       Date:  2012-03-03       Impact factor: 3.481

2.  Plasma gelsolin modulates cellular response to sphingosine 1-phosphate.

Authors:  Robert Bucki; Alina Kulakowska; Fitzroy J Byfield; Malgorzata Zendzian-Piotrowska; Marcin Baranowski; Michal Marzec; Jessamine P Winer; Nicholas J Ciccarelli; Jan Górski; Wieslaw Drozdowski; Robert Bittman; Paul A Janmey
Journal:  Am J Physiol Cell Physiol       Date:  2010-09-01       Impact factor: 4.249

Review 3.  Lysophosphatidic acid type 2 receptor agonists in targeted drug development offer broad therapeutic potential.

Authors:  Gabor J Tigyi; Leonard R Johnson; Sue Chin Lee; Derek D Norman; Erzsebet Szabo; Andrea Balogh; Karin Thompson; Alyssa Boler; W Shannon McCool
Journal:  J Lipid Res       Date:  2019-01-28       Impact factor: 5.922

4.  Recombinant Human Plasma Gelsolin Improves Survival and Attenuates Lung Injury in a Murine Model of Multidrug-Resistant Pseudomonas aeruginosa Pneumonia.

Authors:  Mark J DiNubile; Susan L Levinson; Thomas P Stossel; Matthew B Lawrenz; Jonathan M Warawa
Journal:  Open Forum Infect Dis       Date:  2020-06-19       Impact factor: 3.835

5.  Hypogelsolinemia, a disorder of the extracellular actin scavenger system, in patients with multiple sclerosis.

Authors:  Alina Kułakowska; Nicholas J Ciccarelli; Qi Wen; Barbara Mroczko; Wiesław Drozdowski; Maciej Szmitkowski; Paul A Janmey; Robert Bucki
Journal:  BMC Neurol       Date:  2010-11-01       Impact factor: 2.474

6.  Safety and Pharmacokinetics of Recombinant Human Plasma Gelsolin in Patients Hospitalized for Nonsevere Community-Acquired Pneumonia.

Authors:  Abla Tannous; Susan L Levinson; James Bolognese; Steven M Opal; Mark J DiNubile
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

7.  Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patients.

Authors:  Emmanouil Papasavvas; Maxwell Pistilli; Griffin Reynolds; Robert Bucki; Livio Azzoni; Jihed Chehimi; Paul A Janmey; Mark J DiNubile; Joe Ondercin; Jay R Kostman; Karam C Mounzer; Luis J Montaner
Journal:  AIDS       Date:  2009-01-28       Impact factor: 4.177

8.  Low Admission Plasma Gelsolin Concentrations Identify Community-acquired Pneumonia Patients at High Risk for Severe Outcomes.

Authors:  Wesley H Self; Richard G Wunderink; Mark J DiNubile; Thomas P Stossel; Susan L Levinson; Derek J Williams; Evan J Anderson; Anna M Bramley; Seema Jain; Kathryn M Edwards; Carlos G Grijalva
Journal:  Clin Infect Dis       Date:  2019-09-13       Impact factor: 9.079

9.  Unexpected profile of sphingolipid contents in blood and bone marrow plasma collected from patients diagnosed with acute myeloid leukemia.

Authors:  Marzena Wątek; Bonita Durnaś; Tomasz Wollny; Marcin Pasiarski; Stanisław Góźdź; Michał Marzec; Anna Chabowska; Przemysław Wolak; Małgorzata Żendzian-Piotrowska; Robert Bucki
Journal:  Lipids Health Dis       Date:  2017-12-08       Impact factor: 3.876

10.  Hypogelsolinemia and Decrease in Blood Plasma Sphingosine-1-Phosphate in Patients Diagnosed with Severe Acute Pancreatitis.

Authors:  Tomasz Wollny; Marzena Wątek; Urszula Wnorowska; Ewelina Piktel; Stanisław Góźdź; Krzysztof Kurek; Przemysław Wolak; Grzegorz Król; Małgorzata Żendzian-Piotrowska; Robert Bucki
Journal:  Dig Dis Sci       Date:  2021-02-23       Impact factor: 3.199
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.